Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years.
Anti-MAG polyneuropathy
BAFF
Biomarker
Long-term follow-up
Rituximab
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 12 2019
15 12 2019
Historique:
received:
13
06
2019
revised:
06
09
2019
accepted:
04
10
2019
pubmed:
5
11
2019
medline:
18
6
2020
entrez:
3
11
2019
Statut:
ppublish
Résumé
Rituximab is efficacious in myelin-associated glycoprotein (MAG) polyneuropathy, but the question on timing of retreatments is open. We studied 21 anti-MAG polyneuropathy patients who responded to a first cycle of rituximab, were followed-up for an average of 11.2 years, and were retreated only when relapsing. Baseline serum B-cell-activating factor (BAFF) levels were measured. Clinical improvements lasted on average 6 years, and as many as 71% of the patients resulted long-lasting responders. Severity of disease and high serum BAFF levels (cut-off ≥860 pg/mL for relapse risk) at onset seemed to predict worse prognosis. Measurements of these variables could help deal with the issue of maintenance rituximab therapy in MAG polyneuropathy.
Identifiants
pubmed: 31677562
pii: S0165-5728(19)30304-2
doi: 10.1016/j.jneuroim.2019.577081
pii:
doi:
Substances chimiques
Autoantibodies
0
Immunologic Factors
0
Myelin-Associated Glycoprotein
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
577081Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.